S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48%
Next Bullish Trade
Sign in
MRNA

MRNA

+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · MRNA

Momentum reads · latest daily bar
Last
$61.82
-1.33 (-2.11%)
Mkt cap
$24.5B
Healthcare
RSI(14)
46.1
neutral
Stochastic %K
18.5
oversold
MFI(14)
59.8
neutral
ADX(14)
30.8
trending

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $0.4B $-1.3B $-1.4B $-0.7B -345.2% -356.8%
2025-12-31 $0.7B $-0.8B $-0.9B $0.9B -122.2% -126.8%
2025-09-30 $1.0B $-0.2B $-0.3B $-0.9B -20.0% -25.9%
2025-06-30 $0.1B $-0.8B $-0.9B $-0.9B -602.2% -662.0%
2025-03-31 $0.1B $-1.0B $-1.1B $-1.2B -907.5% -981.3%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare MRNA vs peers

Line MRNA up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing MRNA META× NVDA×
Sector peers + LLY + UNH + JNJ + MRK + ABBV + PFE
Popular + AAPL + MSFT + AMZN + GOOG + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP
No data for: MRNA, META
Verdict
Weighted score 0-100 across 1 tickers · best in green
#1
NVDA
score 50.0
5/5 inputs
EPS growth of 214.5% dominates all categories, driving the top rank despite moderate momentum weakness year-to-date.
value 50growth 50quality 50momentum 50sentiment 50
NVDA
NVIDIA Corporation
$202.81
-2.21%
Snapshot
Price 202.81
Day % -2.21
1M % -2.22
3M % 2.25
YTD % 7.39
Market cap 4912260841472.0
ADV ($) 31818835165.71808
Beta 2.211
OdysseyHQ zone
Current zone Neutral
Dist 21-EMA % -0.9
Dist ATR (σ) -0.25
OdysseyHQ grade —
Confluence 2
Valuation
P/E (ttm) 31.058191
P/E (fwd) 15.80593
P/S 19.378443
EV/EBITDA 30.08
P/B 25.131351
FCF yield 0.0094
PEG 0.65
Growth
Revenue yoy 0.852
EPS yoy 2.145
FCF yoy —
Revenue trend 8Q
Quality
Gross margin 0.74144995
Operating margin 0.65596
Net margin 0.62966
ROE 1.14288
ROA 0.52727
Debt / Equity 0.07
Interest cov. 547.14
Technicals
RSI(14) 48.2
MACD signal bull
vs 50-DMA -3.38
vs 200-DMA 5.41
vs 52w high -14.26
HV-30 41.6
Sentiment
Analyst rec 1.29508
Target upside 48.89
Insider buy-sell 90d -5
Risk
Short interest 1.3300001000000001
Days to cover 1.9
Next earnings 2026-08-26
Full NVDA dashboard →

Earnings replay · last 20 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2026-04-30 -1.18 -3.96 +70.2% -1.2%
2026-02-13 -2.11 -2.64 +20.2% +4.0%
2025-11-06 -0.51 -2.16 +76.4% +0.9%
2025-08-01 -2.13 -3.00 +29.0% +0.1%
2025-05-01 -2.52 -3.11 +18.9% +2.1%
2025-02-14 -2.91 -2.73 -6.7% +8.4%
2024-11-07 0.03 -1.94 +101.5% -6.9%
2024-08-01 -3.33 -3.35 +0.7% -8.1%
2024-05-02 -3.07 -3.57 +14.1% -0.5%
2024-02-22 0.55 -0.99 +155.6% -3.0%
2023-11-02 -9.53 -2.05 -364.4% +8.8%
2023-08-03 -3.62 -4.12 +12.2% -1.6%
2023-05-04 0.19 -1.73 +111.0% +2.0%
2023-02-23 3.61 4.60 -21.5% -5.6%
2022-11-03 2.53 3.11 -18.6% +7.4%
2022-08-03 5.24 4.49 +16.6% +4.1%
2022-05-04 8.58 5.62 +52.6% -8.4%
2022-02-24 11.29 9.81 +15.1% -3.1%
2021-11-04 7.70 9.42 -18.3% -16.6%
2021-08-05 6.46 5.86 +10.3% -0.6%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
MRNA ★ $25B — -15.0 11.0 -9.0 3.3 -69.9% 260.2% — -0.08%
LLY $1,051B 41.5 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 31.8 19.2 0.9 20.2 4.0 18.8% 2.0% 0.7% 4.57%
JNJ $609B 29.0 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0% —
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% — 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.6 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.8 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 48.98%

HolderShares% out
FMR, LLC 45,672,024 11.51%
Blackrock Inc. 29,635,876 7.47%
Vanguard Capital Management LLC 22,872,458 5.76%
BAILLIE GIFFORD & CO 19,985,876 5.04%
Capital World Investors 18,697,694 4.71%
Vanguard Portfolio Management LLC 15,616,367 3.94%
State Street Corporation 14,861,409 3.75%
Geode Capital Management, LLC 9,435,132 2.38%
Two Sigma Investments, LP 9,086,404 2.29%
Morgan Stanley 8,471,263 2.13%

Insider activity · 90d

5 buys / 0 sells · ratio 5.0 · Finnhub

  • McDonnell Michael R. BUY 5,733
  • McDonnell Michael R. BUY 1,618
  • McDonnell Michael R. BUY 7,415
  • Banque Soria Ester BUY 38,364
  • Banque Soria Ester BUY 18,658
  • Mock James M M 1,454
  • Mock James M F 66,436 @ $72.50
  • Mock James M M 67,139
  • Klinger Shannon Thyme M 117,976
  • Klinger Shannon Thyme F 73,561 @ $51.59

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$22.0
Mean
$48.26316
High
$79.0
Analysts
19
Recommendation distribution · period 2026-07-01
4
19
4
3
Revision trend (2026-04-01 → 2026-07-01): net -3 → -3 0 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
4 2026-07-16 PRIMARY DOCUMENT view ·
4 2026-07-10 PRIMARY DOCUMENT view ·
8-K 2026-07-08 8-K view ·
4 2026-07-07 PRIMARY DOCUMENT view ·
4 2026-07-06 PRIMARY DOCUMENT view ·
4 2026-06-17 PRIMARY DOCUMENT view ·
4 2026-06-08 PRIMARY DOCUMENT view ·
4 2026-06-08 PRIMARY DOCUMENT view ·
4 2026-06-03 PRIMARY DOCUMENT view ·
4 2026-06-03 PRIMARY DOCUMENT view ·
4 2026-06-03 PRIMARY DOCUMENT view ·
4 2026-05-29 PRIMARY DOCUMENT view ·
4 2026-05-29 PRIMARY DOCUMENT view ·
4 2026-05-29 PRIMARY DOCUMENT view ·
4 2026-05-22 4 view ·
4 2026-05-18 PRIMARY DOCUMENT view ·
8-K 2026-05-11 8-K view ·
4 2026-05-08 PRIMARY DOCUMENT view ·
4 2026-05-08 PRIMARY DOCUMENT view ·
4 2026-05-08 PRIMARY DOCUMENT view ·
4 2026-05-08 PRIMARY DOCUMENT view ·
4 2026-05-08 PRIMARY DOCUMENT view ·
4 2026-05-08 PRIMARY DOCUMENT view ·
4 2026-05-08 PRIMARY DOCUMENT view ·
4 2026-05-04 PRIMARY DOCUMENT view ·
4 2026-05-04 PRIMARY DOCUMENT view ·
4 2026-05-04 PRIMARY DOCUMENT view ·
4 2026-05-04 PRIMARY DOCUMENT view ·
4 2026-05-04 PRIMARY DOCUMENT view ·
4 2026-05-04 PRIMARY DOCUMENT view ·
10-Q 2026-05-01 10-Q view ·
8-K 2026-05-01 8-K view ·
4 2026-04-06 PRIMARY DOCUMENT view ·
DEF 14A 2026-03-16 DEFINITIVE PROXY STATEMENT view ·
4 2026-03-06 PRIMARY DOCUMENT view ·
4 2026-03-06 PRIMARY DOCUMENT view ·
8-K 2026-03-05 8-K view ·
4 2026-03-03 PRIMARY DOCUMENT view ·
4 2026-03-03 PRIMARY DOCUMENT view ·
4 2026-03-03 PRIMARY DOCUMENT view ·
4 2026-03-03 PRIMARY DOCUMENT view ·
4 2026-02-25 PRIMARY DOCUMENT view ·
10-K 2026-02-20 10-K view ·
4 2026-02-13 PRIMARY DOCUMENT view ·
4 2026-02-13 PRIMARY DOCUMENT view ·
4 2026-02-13 PRIMARY DOCUMENT view ·
4 2026-02-13 PRIMARY DOCUMENT view ·
8-K 2026-02-13 8-K view ·
8-K 2026-02-11 8-K view ·
8-K 2026-01-12 8-K view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
8-K 2026-01-05 8-K view ·
4 2025-12-15 4 view ·
4 2025-12-15 PRIMARY DOCUMENT view ·
4 2025-12-11 PRIMARY DOCUMENT view ·
4 2025-12-08 PRIMARY DOCUMENT view ·
4 2025-12-08 PRIMARY DOCUMENT view ·
4 2025-12-02 PRIMARY DOCUMENT view ·
4 2025-12-02 PRIMARY DOCUMENT view ·
4 2025-12-01 PRIMARY DOCUMENT view ·

About MRNA

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name t…

Options picks · MRNA

ITM + OTM ideas from the latest scan

Loading…

Congress trades · MRNA

STOCK Act disclosures

Loading…

SEC filings & insiders · MRNA

EDGAR · live

Loading…

Holders · MRNA

Institutions & insider activity

Loading…